接连遭举报，疫苗明星沃森生物缘何惹怒投资者？

Core Viewpoint - Watson Bio has faced significant governance issues, including high executive salaries without proper approval, leading to investor concerns and regulatory scrutiny [1][3][4]. Group 1: Executive Compensation Issues - Watson Bio's executives received substantial salary increases without shareholder approval, with the chairman's salary rising from 1.45 million in 2020 to 4.33 million in 2023, significantly above the industry average of 1.85 million [4][7]. - The overall executive compensation increased by nearly 10 million in 2023 compared to 2022, despite a 19.12% decline in revenue and a 42.44% drop in net profit [8][7]. - Investors have raised alarms about the disconnect between executive pay and company performance, with many feeling that management is prioritizing personal financial gain over shareholder interests [8][10]. Group 2: Financial Performance and Governance Concerns - Watson Bio's revenue fell by 19.12% in 2023 and is projected to decline by 31.41% in 2024, with net profit dropping by 66.10% [8][23]. - The company has been criticized for its governance structure, which lacks effective oversight, allowing executives to make decisions without adequate checks and balances [10][12]. - Investors have reported that the independent directors have not adequately addressed governance issues, leading to a perception of collusion between management and the board [10][12]. Group 3: Cash Flow and Financial Health - Watson Bio's cash flow from operating activities plummeted by 85.75%, indicating a severe decline in its ability to generate cash from its core vaccine business [22][24]. - The company has engaged in significant cash outflows, including 7.6 billion in dividends to minority shareholders, while simultaneously pledging core assets for loans, raising concerns about its financial stability [18][20]. - As of the end of Q3 2025, the company's cash reserves decreased from 3.76 billion to 1.68 billion, highlighting a critical liquidity crisis [20][24]. Group 4: Shareholder Relations and Market Confidence - Watson Bio's stock price has seen a dramatic decline, falling from around 36 to approximately 15, leading to investor dissatisfaction and calls for accountability [15][17]. - The company's commitment to a share buyback program has been perceived as insincere, with only minimal execution against a backdrop of significant share price depreciation [14][15]. - The termination of the Hong Kong IPO plan further constrains the company's financial options, exacerbating investor concerns about its future [24][25].